vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and SHOPIFY INC. (SHOP). Click either name above to swap in a different company.
SHOPIFY INC. is the larger business by last-quarter revenue ($3.7B vs $2.8B, roughly 1.3× Bausch Health Companies Inc.). SHOPIFY INC. runs the higher net margin — 20.2% vs -3.7%, a 23.9% gap on every dollar of revenue. On growth, SHOPIFY INC. posted the faster year-over-year revenue change (30.6% vs 9.3%). SHOPIFY INC. produced more free cash flow last quarter ($715.0M vs $403.0M). Over the past eight quarters, SHOPIFY INC.'s revenue compounded faster (40.5% CAGR vs 14.0%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Shopify Inc., stylized as shopify, is a Canadian multinational e-commerce company headquartered in Ottawa, Ontario that operates a platform for retail point-of-sale systems. The company has over 5 million customers and processed US$292.3 billion in transactions in 2024, of which 57% was in the United States. Major customers include Tesla, LVMH, Nestlé, PepsiCo, AB InBev, Kraft Heinz, Lindt, Whole Foods Market, Red Bull, and Hyatt.
BHC vs SHOP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $3.7B |
| Net Profit | $-103.0M | $743.0M |
| Gross Margin | — | 46.1% |
| Operating Margin | 17.0% | 17.2% |
| Net Margin | -3.7% | 20.2% |
| Revenue YoY | 9.3% | 30.6% |
| Net Profit YoY | -205.1% | -42.5% |
| EPS (diluted) | $-0.30 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $3.7B | ||
| Q3 25 | $2.7B | $2.8B | ||
| Q2 25 | $2.5B | $2.7B | ||
| Q1 25 | $2.3B | $2.4B | ||
| Q4 24 | $2.6B | $2.8B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.4B | $2.0B | ||
| Q1 24 | $2.2B | $1.9B |
| Q4 25 | $-103.0M | $743.0M | ||
| Q3 25 | $179.0M | $264.0M | ||
| Q2 25 | $148.0M | $906.0M | ||
| Q1 25 | $-58.0M | $-682.0M | ||
| Q4 24 | $98.0M | $1.3B | ||
| Q3 24 | $-85.0M | $828.0M | ||
| Q2 24 | $10.0M | $171.0M | ||
| Q1 24 | $-64.0M | $-273.0M |
| Q4 25 | — | 46.1% | ||
| Q3 25 | — | 48.9% | ||
| Q2 25 | — | 48.6% | ||
| Q1 25 | — | 49.5% | ||
| Q4 24 | — | 48.1% | ||
| Q3 24 | — | 51.7% | ||
| Q2 24 | — | 51.1% | ||
| Q1 24 | — | 51.4% |
| Q4 25 | 17.0% | 17.2% | ||
| Q3 25 | 23.1% | 12.1% | ||
| Q2 25 | 17.5% | 10.9% | ||
| Q1 25 | 12.2% | 8.6% | ||
| Q4 24 | 21.8% | 16.5% | ||
| Q3 24 | 12.7% | 13.1% | ||
| Q2 24 | 16.2% | 11.8% | ||
| Q1 24 | 13.1% | 4.6% |
| Q4 25 | -3.7% | 20.2% | ||
| Q3 25 | 6.7% | 9.3% | ||
| Q2 25 | 5.8% | 33.8% | ||
| Q1 25 | -2.6% | -28.9% | ||
| Q4 24 | 3.8% | 46.0% | ||
| Q3 24 | -3.4% | 38.3% | ||
| Q2 24 | 0.4% | 8.4% | ||
| Q1 24 | -3.0% | -14.7% |
| Q4 25 | $-0.30 | $0.58 | ||
| Q3 25 | $0.48 | $0.20 | ||
| Q2 25 | $0.40 | $0.69 | ||
| Q1 25 | $-0.16 | $-0.53 | ||
| Q4 24 | $0.24 | $0.99 | ||
| Q3 24 | $-0.23 | $0.64 | ||
| Q2 24 | $0.03 | $0.13 | ||
| Q1 24 | $-0.17 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $5.8B |
| Total DebtLower is stronger | $20.8B | — |
| Stockholders' EquityBook value | $-554.0M | $13.5B |
| Total Assets | $26.4B | $15.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $5.8B | ||
| Q3 25 | $1.3B | $6.3B | ||
| Q2 25 | $1.7B | $5.8B | ||
| Q1 25 | $1.1B | $5.5B | ||
| Q4 24 | $1.2B | $5.5B | ||
| Q3 24 | $719.0M | — | ||
| Q2 24 | $595.0M | — | ||
| Q1 24 | $733.0M | — |
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
| Q4 25 | $-554.0M | $13.5B | ||
| Q3 25 | $-565.0M | $12.5B | ||
| Q2 25 | $-764.0M | $12.1B | ||
| Q1 25 | $-1.2B | $11.1B | ||
| Q4 24 | $-1.3B | $11.6B | ||
| Q3 24 | $-1.2B | $10.1B | ||
| Q2 24 | $-1.2B | $9.2B | ||
| Q1 24 | $-1.1B | $8.9B |
| Q4 25 | $26.4B | $15.2B | ||
| Q3 25 | $26.8B | $15.0B | ||
| Q2 25 | $27.3B | $14.6B | ||
| Q1 25 | $26.4B | $13.4B | ||
| Q4 24 | $26.5B | $13.9B | ||
| Q3 24 | $26.5B | — | ||
| Q2 24 | $26.5B | — | ||
| Q1 24 | $26.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $725.0M |
| Free Cash FlowOCF − Capex | $403.0M | $715.0M |
| FCF MarginFCF / Revenue | 14.4% | 19.5% |
| Capex IntensityCapex / Revenue | 3.3% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 0.98× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $2.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $725.0M | ||
| Q3 25 | $405.0M | $513.0M | ||
| Q2 25 | $289.0M | $428.0M | ||
| Q1 25 | $211.0M | $367.0M | ||
| Q4 24 | $601.0M | $615.0M | ||
| Q3 24 | $405.0M | $423.0M | ||
| Q2 24 | $380.0M | $340.0M | ||
| Q1 24 | $211.0M | $238.0M |
| Q4 25 | $403.0M | $715.0M | ||
| Q3 25 | $314.0M | $507.0M | ||
| Q2 25 | $190.0M | $422.0M | ||
| Q1 25 | $96.0M | $363.0M | ||
| Q4 24 | $495.0M | $611.0M | ||
| Q3 24 | $334.0M | $421.0M | ||
| Q2 24 | $302.0M | $333.0M | ||
| Q1 24 | $129.0M | $232.0M |
| Q4 25 | 14.4% | 19.5% | ||
| Q3 25 | 11.7% | 17.8% | ||
| Q2 25 | 7.5% | 15.7% | ||
| Q1 25 | 4.2% | 15.4% | ||
| Q4 24 | 19.3% | 21.7% | ||
| Q3 24 | 13.3% | 19.5% | ||
| Q2 24 | 12.6% | 16.3% | ||
| Q1 24 | 6.0% | 12.5% |
| Q4 25 | 3.3% | 0.3% | ||
| Q3 25 | 3.4% | 0.2% | ||
| Q2 25 | 3.9% | 0.2% | ||
| Q1 25 | 5.1% | 0.2% | ||
| Q4 24 | 4.1% | 0.1% | ||
| Q3 24 | 2.8% | 0.1% | ||
| Q2 24 | 3.2% | 0.3% | ||
| Q1 24 | 3.8% | 0.3% |
| Q4 25 | — | 0.98× | ||
| Q3 25 | 2.26× | 1.94× | ||
| Q2 25 | 1.95× | 0.47× | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | 0.48× | ||
| Q3 24 | — | 0.51× | ||
| Q2 24 | 38.00× | 1.99× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
SHOP
| Services | $2.9B | 79% |
| Subscription And Circulation | $777.0M | 21% |
